NCT07007312 2026-04-09
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Kura Oncology, Inc.
Phase 3 Recruiting
Kura Oncology, Inc.
Daiichi Sankyo
Gilead Sciences
Daiichi Sankyo
Amgen
Novartis
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Pfizer
Jazz Pharmaceuticals
Antisoma Research
NIH AIDS Clinical Trials Information Service